VRTX
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc historical holders
total: 4
Egerton Capital Vertex Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2024 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2024 Q4
John Armitage has been an institutional investor in Vertex Pharmaceuticals Inc (VRTX) since 2024 Q3. According to 2026 Q2 report, John Armitage doesn't hold any shares. The fund/company first acquired VRTX in 2024 Q3, initially purchasing 124,045 shares. Since the initial investment, Egerton Capital has made 1 more transaction in this position.
When did John Armitage exit their VRTX position?
John Armitage no longer holds Vertex Pharmaceuticals Inc (VRTX). They sold off their entire position in 2024 Q4, closing out an investment that began in 2024 Q3.
When did John Armitage first invest in VRTX?
John Armitage first invested in Vertex Pharmaceuticals Inc (VRTX) in 2024 Q3 at the reported quarter-end price of $465.08 per share, acquiring 124,045 shares in their initial purchase.
What is John Armitage's average cost basis for VRTX?
Based on historical transaction data, John Armitage's estimated cost basis for Vertex Pharmaceuticals Inc (VRTX) is approximately $465.08 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $465.08
- Weighted AVG sell price:
- $465.08
VRTX transactions history by Egerton Capital
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.00%
|
0
|
$465.08
|
|
-100% (-124,045)
|
-0.58%
|
|
2024 Q3
|
0.58%
|
124,045
|
$465.08
|
$57,690,849
|
new
|
+0.58%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.